Status:
COMPLETED
Prospective Study for the Application of Cytosorb® in Critically Ill Patients
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Conditions:
Rhabdomyolysis
Acute Liver Injury
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The mortality of critically ill patients is persistently high and requires targeted therapy of pathophysiological disorders. One approach to optimize therapy is the use of the cytokine adsorber Cytoso...
Eligibility Criteria
Inclusion
- intensive care therapy
- hyperinflammation or acute liver dysfunction or rhabdomyolysis
- need of continuous renal replacement therapy
- treatment with Cytosorb (decision of the attending physician)
Exclusion
- \- other reasons for Cytosorb application
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT04913298
Start Date
March 1 2021
End Date
December 15 2023
Last Update
February 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LMU munich
Munich, Bavaria, Germany, 81377